News & Events

HighTide Therapeutics Announces Regulatory Approvals For Expanded Clinical Development of HTD1801

November 19, 2019

Approvals Support Clinical Trials in China and Canada

for HTD1801 in Primary Sclerosing Cholangitis


SHENZHEN, CHINA and ROCKVILLE, MD, November 19, 2019 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced that it has received investigational new drug (IND) application approval from the National Medical Products Administration of China, and also a No Objection Letter (NOL) from Health Canada, for HTD1801. These regulatory milestones support the Company’s plans to initiate proof of concept clinical trials of HTD1801 for primary sclerosing cholangitis (PSC) outside the U.S.

“These two regulatory approvals are part of our plan to increase the number of countries in which we conduct clinical trials of HTD1801 for PSC, and reflect HighTide’s plans to help patients on a global scale,” said Liping Liu, Ph.D., Founder and Chief Executive Officer of HighTide. “We would like to thank the thought-leading investigators in China and Canada who have to date expressed interest in helping us conduct these studies.”


About PSC


Primary sclerosing cholangitis (PSC) is a chronic, progressive liver disease characterized by inflammation and fibrosis of the bile ducts, leading to the formation of multifocal bile duct strictures. This cholestatic disease deteriorates to fibrosis, cirrhosis and ultimately liver failure, with an increased risk of malignancy. Currently, there are no approved therapies for PSC.


About HighTide Therapeutics


HighTide Therapeutics Inc., founded in 2011 in Shenzhen, China, is dedicated to the discovery and development of innovative therapeutics for people suffering from non-viral chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unsatisfied market needs. HTD1801, HighTide’s lead program, is a new molecular entity being developed for the treatment of NASH and PSC. HTD1801 has received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. HTD1801 is currently in Phase 2 proof of concept trials for NASH and PSC in the U.S., with topline data expected in 2020. HighTide also has compounds in development for metabolic and GI diseases, including HTD4010 for Pancreatitis. For additional information, please visit www.hightidetx.com.


Contacts:


Jeffrey Dao
ir@hightidetx.com


Laurence Watts

laurence@gilmartinir.com

Share on WeChat circle of friends ×
Open WeChat
Use Scan to share web pages with your friends.

We will contact you as soon as possible

© 2019 HighTide Therapeutics Inc.

Legal StatementPrivacy PolicyCookie Policy

收起
En

Follow Us

© 2019 HighTide Therapeutics Inc.